Peer-reviewed veterinary case report
Kidney injury markers in dogs with bloat treated with lidocaine or not
By Lehmann, Anna et al.·Published in Frontiers in veterinary science·2023·Department of Clinical Veterinary Science·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Concentrations and kinetics of renal biomarkers in dogs with gastric dilatation-volvulus with and without 24-h intravenous lidocaine.
- Species:
- dog
Plain-English summary
A group of dogs with gastric dilatation-volvulus (GDV), a serious condition that can lead to kidney injury, were studied to see if intravenous lidocaine could help protect their kidneys. The dogs were divided into two groups: one received lidocaine during treatment, while the other did not. Researchers measured various kidney markers before and after surgery. They found that while kidney markers increased in both groups after surgery, there was no significant difference between the dogs that received lidocaine and those that did not. This suggests that lidocaine did not provide the expected kidney protection in these cases.
People also search for: dog GDV treatment · kidney injury in dogs · lidocaine for dogs with GDV
Abstract
BACKGROUND: Gastric dilatation volvulus (GDV) can lead to organ failure including acute kidney injury (AKI). Due to its cytoprotective, antioxidant and anti-inflammatory effects, lidocaine has a potential to prevent AKI in dogs with GDV. DESIGN AND SETTING: Prospective, observational cohort study in client-owned dogs with GDV. OBJECTIVE: To determine concentrations of renal biomarkers for AKI in dogs with GDV with and without intravenous (IV) lidocaine therapy. METHODS: Thirty-two dogs were randomized to receive either IV lidocaine (2 mg/kg, followed by a lidocaine constant rate infusion at a dose of 50 μg/kg/min over 24 h;= 17) or no lidocaine (= 15). Blood and urine samples were taken at admission () (only blood), during or immediately after surgery (), and 24 () and 48 () h after surgery. Plasma creatinine (pCr), plasma neutrophil gelatinase-associated lipocalin (pNGAL), urinary NGAL (uNGAL), uNGAL to creatinine ratio (UNCR), and urinary gamma-glutamyl transferase to creatinine ratio (uGGT/uCr) were evaluated. Biomarker concentrations were compared between dogs with and without IV lidocaine and the course of each marker was determined in comparison to its admission value. RESULTS: In the entire population, a significantly higher pCr at(median, 95 μmol/L, interquartile range, 82-105) compared with(69 μmol/L, 60-78),(63 μmol/L, 52-78), and(78 μmol/L, 65-87) (< 0.001) was found. Plasma NGAL increased significantly between(5.66 ng/mL, 3.58-7.43) and(7.50 ng/mL, 4.01-11.89) (= 0.006) and(9.86 ng/mL, 5.52-13.92) (< 0.001), respectively. Urinary NGAL increased significantly between(0.61 ng/mL, 0.30-2.59) and(2.62 ng/mL, 1.86-10.92) (= 0.001) and(4.79 ng/mL, 1.96-34.97 (< 0.001), respectively. UNCR increased significantly between(0.15 μg/mmol, 0.09-0.54) and(1.14 μg/mmol, 0.41-3.58) (= 0.0015) and(1.34 μg/mmol, 0.30-7.42) (< 0.001), respectively. Concentrations of uGGT/uCr increased significantly fromhighest at(6.20 U/mmol, 3.90-9.90) and significantly decreased at(3.76 U/mmol, 2.84-6.22) (< 0.001). No significant differences in any renal biomarker concentration were found between dogs with and without IV lidocaine therapy. CONCLUSION AND CLINICAL RELEVANCE: Plasma NGAL, uNGAL and UNCR remained increased up to 48 h post-surgery. No evidence of lidocaine-associated renoprotection was found.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36846247/